Clinical Trials on Lung Cancer NOS

Total 110413 results

National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Stage IIIA Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
Peking University People's Hospital
Guangzhou Burning Rock Medical Examination Institute Co., Ltd.

Not yet recruiting

Evolution of Multiple Primary Lung Cancer (Evolution)

Lung Cancer | Non Small Cell Lung Cancer | Multiple Primary Lung Cancers
Wake Forest University Health Sciences
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
National Cancer Institute, Naples

Active, not recruiting

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy (PETRA)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Metastatic Lung Cancer | Advanced Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | Squamous Cell Lung Cancer

United States
Tesaro, Inc.

Active, not recruiting

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Neoplasms | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Recruiting

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer (SORT)

Non Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States, Canada
GlaxoSmithKline

Completed

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell | Non-Small-Cell Lung Cancer

United States, Canada, Poland
University of Southern California
National Cancer Institute (NCI)

Terminated

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Wake Forest University Health Sciences
AstraZeneca; Atrium Health Levine Cancer Institute

Active, not recruiting

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Non Small Cell Lung Cancer | Lung Cancer Stage III | Lung Cancer Stage II

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, United Kingdom, Spain
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Metastatic | Nonsquamous Non-Small Cell Neoplasm of Lung | Non-Small Cell Lung Cancer Stage IIIB

United Kingdom, Sweden
Lawson Health Research Institute

Recruiting

Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer (Pre-PLaN)

Non-small Cell Lung Cancer Stage IB (Resectable) | Non-small Cell Lung Cancer Stage II (Resectable) | Non-small Cell Lung Cancer Stage ⅢA (Resectable)

Canada
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Italy, Mexico, Poland, Romania, Spain, Switzerland, United Kingdom, Ireland, Netherlands
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer

United States
Luye Pharma Group Ltd.

Unknown

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

China
City of Hope Medical Center
OSI Pharmaceuticals

Completed

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Oslo University Hospital
AstraZeneca

Active, not recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

Cancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage III

Norway, Finland, Lithuania, Estonia
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Terminated

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Head and Neck Cancer | Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Adult Solid Neoplasm

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Non-small Cell Lung Cancer | EGFR-mutant Lung Cancers

United States
National University Hospital, Singapore

Recruiting

Osimertinib for Advanced EGFR-positive NSCLC Patients

Non Small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Singapore
Greg Durm, MD
AstraZeneca; Indiana University School of Medicine

Terminated

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer

United States
National Cancer Institute, Naples

Active, not recruiting

MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer (MILES-3)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
Zhejiang Provincial People's Hospital

Withdrawn

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer | Radiotherapy | Metastatic Non-small Cell Lung Cancer | Thymalfasin
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
First People's Hospital of Hangzhou

Completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Gradalis, Inc.

Withdrawn

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom

Clinical Trials on Lung Cancer NOS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations